DBVT DBV Technologies S.A.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1613780 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-31.5%
TTM net income YoY-65.6%
TTM EPS YoY42.3%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,418.8%
Net margin-5,392.2%
FCF margin-4,986.9%
EBITDA margin—
Returns
ROE-205.8%
ROA-127.2%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue87.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.60M | $700,000 | $900,000 | $645,000 | $2.80M | $1.50M | $800,000 | $511,000 |
| R&D expense | $47.00M | $31.20M | $33.40M | $32.89M | $28.60M | $33.70M | $21.50M | $18.90M |
| SG&A expense | $14.00M | $14.60M | $10.50M | $11.44M | $7.30M | $8.50M | $5.60M | $5.07M |
| Operating income | -$64.80M | -$50.60M | -$47.90M | -$45.05M | -$34.30M | -$41.10M | -$26.60M | -$23.86M |
| Pretax income | -$64.20M | -$50.20M | -$47.40M | -$44.46M | -$33.20M | -$41.80M | -$27.10M | -$23.01M |
| Income tax | $300,000 | $200,000 | $200,000 | $374,000 | $0 | $100,000 | $0 | $7,000 |
| Net income | -$64.50M | -$50.40M | -$47.60M | -$44.83M | -$33.20M | -$41.90M | -$27.10M | -$23.02M |
| EBITDA | -$64.20M | — | — | — | — | — | — | — |
| EPS (basic) | -0.14 | -0.12 | -0.11 | — | -0.24 | -0.31 | -0.26 | — |
| EPS (diluted) | -0.14 | -0.12 | -0.11 | — | -0.24 | -0.31 | -0.26 | — |
| Weighted avg. shares (diluted) | 451.03M | 433.54M | 428.30M | — | 136.81M | 134.48M | 102.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $165.70M | $174.90M | $229.20M | $194.20M | $69.80M | $103.20M | $13.00M | $32.50M |
| Current assets | $189.60M | $201.90M | $246.70M | $212.90M | $88.88M | $121.24M | $29.15M | $44.39M |
| PP&E, net | $11.50M | $9.70M | $9.90M | $10.40M | $10.54M | $11.05M | $10.81M | $11.31M |
| Intangibles | — | — | $100,000 | $0 | $21,000 | $26,000 | $29,000 | $40,000 |
| Total assets | $215.40M | $223.20M | $266.40M | $233.70M | $110.50M | $143.43M | $50.56M | $65.66M |
| Current liabilities | $58.50M | $54.30M | $51.80M | $58.00M | $49.48M | $49.42M | $40.38M | $31.14M |
| Long-term debt | $200,000 | — | — | $0 | — | — | — | — |
| Total debt | $200,000 | — | — | $0 | — | — | — | — |
| Total liabilities | $66.70M | $62.80M | $58.40M | $64.90M | $57.64M | $57.20M | $47.69M | $38.27M |
| Shareholders' equity | $148.60M | $160.40M | $207.90M | $168.80M | $52.90M | $86.20M | $2.90M | $27.40M |
| Net debt | -$165.50M | — | — | -$194.20M | — | — | — | — |
| Shares outstanding | — | — | — | — | 136.98M | 136.97M | 102.86M | 102.85M |
| Cash flow statement | ||||||||
| Operating cash flow | -$51.50M | -$52.60M | -$49.10M | -$35.17M | -$32.40M | -$33.90M | -$19.70M | -$12.25M |
| Capital expenditure | $2.20M | $400,000 | $400,000 | $373,000 | $200,000 | $0 | $0 | -$125,000 |
| Free cash flow | -$53.70M | -$53.00M | -$49.50M | -$35.55M | -$32.60M | -$33.90M | -$19.70M | -$12.13M |
| Investing cash flow | -$5.30M | -$600,000 | -$300,000 | -$715,000 | -$300,000 | $0 | -$400,000 | $793,000 |
| Financing cash flow | $48.10M | $100,000 | $88.90M | $159.06M | $100,000 | $117.00M | $0 | $675,000 |
| Depreciation & amortization | $600,000 | — | — | — | — | — | — | — |
| Stock-based compensation | $5.00M | $3.70M | $2.30M | $1.92M | $500,000 | $1.20M | $1.70M | -$453,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.